From gene expression to serum proteins: biomarker discovery in ankylosing spondylitis

Objectives:Studying post-infliximab gene expression changes could provide insights into the pathogenesis of ankylosing spondylitis (AS).Methods:Gene expression changes were screened by microarray on peripheral blood RNA of 16 AS patients at baseline and 2 weeks post-infliximab, and selected results...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Annals of the rheumatic diseases Ročník 69; číslo 1; s. 297 - 300
Hlavní autori: Haroon, N, Tsui, F W L, O’Shea, F D, Chiu, B, Tsui, H W, Zhang, H, Marshall, K W, Inman, R D
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England BMJ Publishing Group Ltd and European League Against Rheumatism 01.01.2010
Elsevier Limited
Predmet:
Adult
Antibodies, Monoclonal - therapeutic use
Antirheumatic Agents - therapeutic use
Biomarkers - blood
Blood Proteins - metabolism
Blood Sedimentation
C-Reactive Protein - metabolism
Disease
Female
Gene expression
Gene Expression Profiling - methods
Humans
Hypotheses
Infliximab
Laboratories
Light
Male
Middle Aged
Oligonucleotide Array Sequence Analysis - methods
Patients
Reverse Transcriptase Polymerase Chain Reaction - methods
Severity of Illness Index
Spondylitis, Ankylosing - blood
Spondylitis, Ankylosing - drug therapy
Tumor Necrosis Factor Ligand Superfamily Member 14 - blood
Tumor necrosis factor-TNF
Young Adult
California
ISSN:0003-4967, 1468-2060, 1468-2060
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Objectives:Studying post-infliximab gene expression changes could provide insights into the pathogenesis of ankylosing spondylitis (AS).Methods:Gene expression changes were screened by microarray on peripheral blood RNA of 16 AS patients at baseline and 2 weeks post-infliximab, and selected results were confirmed by quantitative real-time (qRT)–PCR. Corresponding serum-soluble LIGHT (sLIGHT) was estimated by ELISA and the fold change in sLIGHT was correlated to the fold change in erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and the Bath AS disease activity index.Results:Post-infliximab, 69% of the patients (11/16) achieved an ASAS20 response. Six candidate genes were differentially expressed by microarray; four of which were validated by qRT–PCR. sLIGHT showed the most significant difference. There was good correlation of baseline sLIGHT with CRP (R  =  0.60; p = 0.01) and ESR (R  =  0.51; p = 0.04). The fold change in sLIGHT correlated with change in both CRP (R  =  0.71, p = 0.002) and ESR (R  =  0.77, p<0.001).Conclusion:LIGHT is significantly downregulated by infliximab. sLIGHT correlated well with changes in inflammatory markers.
Bibliografia:href:annrheumdis-69-297.pdf
istex:BA3D67BDD5F611A2DF5A63C20D28626E1DA82F35
ark:/67375/NVC-KQKWCLDQ-3
ArticleID:ar102277
local:annrheumdis;69/01/297
PMID:19103635
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0003-4967
1468-2060
1468-2060
DOI:10.1136/ard.2008.102277